Matrix metalloproteinase inhibitors 1998

被引：123

作者：

Beckett, RP ^{[1
]}

Whittaker, M ^{[1
]}

机构：

[1] British Biotech Pharmaceut Ltd, Dept Med Chem, Oxford OX4 5LY, England

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 1998年 / 8卷 / 03期

关键词：

arthritis; cancer; collagenase; gelatinase; matrix metalloproteinase; stromelysin; tumour necrosis factor-alpha;

D O I：

10.1517/13543776.8.3.259

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Inhibition of matrix metalloproteinases (MMPs) as an approach to treatment of diseases such as cancer, arthritis and multiple sclerosis (MS) is now an area of intense interest within the pharmaceutical industry. This review summarises developments in the design and clinical evaluation of synthetic MMP inhibitors since the subject was last covered in this journal in 1996.

引用

页码：259 / 282

页数：24

共 85 条

[21] Potent carboxylate inhibitors of stromelysin containing P2' piperazic acids and P1' biaryl moeities [J].

Cherney, RJ ;

Decicco, CP ;

Nelson, DJ ;

Wang, L ;

Meyer, DT ;

Hardman, KD ;

Copeland, RA ;

Arner, EC .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (13) :1757-1762

[22] Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor [J].

Clements, JM ;

Cossins, JA ;

Wells, GMA ;

Corkill, DJ ;

Helfrich, K ;

Wood, LM ;

Pigott, R ;

Stabler, G ;

Ward, GA ;

Gearing, AJH ;

Miller, KM .

JOURNAL OF NEUROIMMUNOLOGY, 1997, 74 (1-2) :85-94

[23] THE INFLUENCE OF PEPTIDE STRUCTURE ON TRANSPORT ACROSS CACO-2 CELLS .2. PEPTIDE-BOND MODIFICATION WHICH RESULTS IN IMPROVED PERMEABILITY [J].

CONRADI, RA ;

HILGERS, AR ;

HO, NFH ;

BURTON, PS .

PHARMACEUTICAL RESEARCH, 1992, 9 (03) :435-439

[24]

Davidson AH, 1997, CHEM IND-LONDON, P258

[25]

DAVIES SJ, 1997, 9 RSC SCI MED CHEM S

[26] Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics [J].

Decicco, CP ;

Seng, JL ;

Kennedy, KE ;

Covington, MB ;

Welch, PK ;

Arner, EC ;

Magolda, RL ;

Nelson, DJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (18) :2331-2336

[27]

DECICCO CP, 1997, SRI RAND RAT C PRINC

[28] Matrix metalloproteinase inhibitors: Present achievements and future prospects [J].

Denis, LJ ;

Verweij, J .

INVESTIGATIONAL NEW DRUGS, 1997, 15 (03) :175-185

[29] Rifamycins as inhibitors of collagenase activity: Their possible pharmacological role in collagen degradative diseases [J].

DiGiulio, A ;

Barracchini, A ;

Cellai, L ;

Martuccio, C ;

Amicosante, G ;

Oratore, A ;

Pantaleoni, G .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 144 (01) :27-35

[30] Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing [J].

DiMartino, M ;

Wolff, C ;

High, W ;

Stroup, G ;

Hoffman, S ;

Laydon, J ;

Lee, JC ;

Bertolini, D ;

Galloway, WA ;

Crimmin, MJ ;

Davis, M ;

Davies, S .

INFLAMMATION RESEARCH, 1997, 46 (06) :211-215

← 1 2 3 4 5 6 7 8 9 →